M142.8 Antibody

What is the M1/42.3.9.8 antibody and what epitopes does it recognize?

The M1/42.3.9.8 antibody is a rat anti-mouse monoclonal antibody that specifically recognizes H-2 antigens, which are mouse major histocompatibility complex (MHC) class I molecules. This antibody has broad reactivity, binding to H-2 antigens from cells of multiple haplotypes including a, b, d, j, k, s, and u (all haplotypes that have been tested) . The antibody's specificity for MHC class I molecules makes it a valuable tool for immunological research, particularly in studying antigen presentation, immune recognition, and histocompatibility .

How does the M1/42.3.9.8 antibody compare to other anti-MHC class I antibodies?

The M1/42.3.9.8 antibody distinguishes itself through its broad reactivity across multiple H-2 haplotypes, whereas many other anti-MHC antibodies are haplotype-specific. For example, when used in series with the H-2Kk-specific monoclonal antibody 11-4.1, researchers have successfully purified Dk and Dd from RDM-4 and YAC cells, respectively . This versatility enables researchers to conduct comparative studies across different mouse strains without changing detection reagents, providing consistent experimental conditions. The antibody maintains high specificity while offering this broad reactivity, making it particularly useful for studies requiring detection of MHC class I molecules across various genetic backgrounds .

What are the typical applications for the M1/42.3.9.8 antibody?

The M1/42.3.9.8 antibody has several important applications in immunological research:

These applications make the antibody particularly valuable for researchers investigating immune recognition, histocompatibility, and immune cell interactions .

How can the M1/42.3.9.8 antibody be used to establish purification protocols for MHC class I molecules?

The M1/42.3.9.8 antibody has been successfully employed for affinity chromatography-based purification of MHC class I molecules, enabling researchers to obtain relatively large quantities of functionally active H-2 antigens. The established methodology involves:

• Coupling the M1/42.3.9.8 antibody to Sepharose-4B beads to create an affinity matrix

• Applying cell lysate (typically in detergent) to the column

• Washing to remove non-specifically bound proteins

• Eluting bound H-2 molecules using 0.5% DOC, 0.65 M NaCl, 20 mM Tris, pH 8.0 buffer

This approach has been documented to yield 110-180 micrograms of H-2d from 10^10 P815 tumor cells . The purified H-2 molecules retain both serological and biological activity, as demonstrated by:

• Ability to rebind monoclonal antibodies

• Capacity to inhibit cell lysis by alloantisera plus complement

• Retention of ability to stimulate alloreactive cytotoxic T lymphocytes (CTL)

For sequential purification of specific MHC alleles, researchers can implement a strategy using M1/42.3.9.8 in series with haplotype-specific antibodies (e.g., H-2Kk-specific MAb 11-4.1) to isolate individual MHC molecules such as Dk and Dd from mixed populations .

What considerations should be taken into account when designing experiments to quantitate H-2 expression levels?

When designing experiments to quantitate H-2 expression levels using the M1/42.3.9.8 antibody, researchers should consider several important factors:

• Antibody titration: It is recommended to titrate the antibody for optimal performance. The suggested starting concentration is ≤0.25 μg per 10^6 cells in 100 μL volume or 100 μL of whole blood .

• Secondary detection system: When using indirect detection methods such as FITC-conjugated anti-rat Ig, standardization of the secondary reagent is crucial for reliable quantitation .

• Control samples: Include appropriate isotype controls such as AF/LE Purified Rat IgG2a, κ Isotype Control [2A3] to assess non-specific binding .

• Cell type variations: Different cell types may express varying levels of MHC class I molecules. The M1/42.3.9.8 antibody has been validated for quantitation of H-2 expression across multiple cell types, making it useful for comparative studies .

• Experimental validation: Prior to large-scale experiments, validation with known positive and negative controls is essential to confirm antibody specificity in the experimental system being used .

• Technical replicates: Include technical replicates to account for staining variability and ensure reproducible quantitation of expression levels.

How can researchers validate the specificity of M1/42.3.9.8 antibody in their experimental system?

Validation of antibody specificity is critical for ensuring reliable experimental results. For the M1/42.3.9.8 antibody, researchers should implement a multi-faceted validation approach:

• Genetic validation: Test the antibody on cells from MHC class I knockout mice as negative controls, which should show absence of staining.

• Haplotype panel testing: Confirm reactivity across multiple H-2 haplotypes (a, b, d, j, k, s, and u) as reported in the literature .

• Competitive binding assays: Perform pre-blocking experiments with unlabeled antibody to demonstrate specific epitope recognition.

• Western blot analysis: Verify binding to proteins of the expected molecular weight (~45 kDa for MHC class I heavy chain).

• Application-specific validation: For each experimental application (flow cytometry, immunoprecipitation, etc.), perform specific validation tests:

  • For flow cytometry: Compare staining patterns with other validated anti-MHC class I antibodies

  • For immunoprecipitation: Confirm identity of precipitated proteins by mass spectrometry

  • For affinity purification: Assess purity and functionality of isolated molecules

• Cross-reactivity assessment: Test for potential cross-reactivity with other proteins, particularly other members of the immunoglobulin superfamily that share structural similarities with MHC molecules.

As noted in the literature: "peer reviewers would want to see data to support that your antibody is specific and sensitive in the applications and assays that you use it in" . Therefore, comprehensive validation is essential before proceeding with full-scale experiments.

What are the optimal conditions for using M1/42.3.9.8 antibody in flow cytometry?

For optimal flow cytometry results with the M1/42.3.9.8 antibody, researchers should consider the following protocol parameters:

What approaches can be used to resolve contradictory results when working with M1/42.3.9.8 antibody?

When encountering contradictory results with the M1/42.3.9.8 antibody, researchers should systematically troubleshoot using the following approaches:

• Antibody validation reassessment:

  • Confirm antibody specificity using known positive and negative controls

  • Verify antibody functionality with alternative detection methods

  • Check for batch variations by comparing lot numbers

• Technical parameter optimization:

  • Titrate the antibody across a wider concentration range

  • Modify incubation conditions (time, temperature, buffer composition)

  • Test alternative fixation and permeabilization protocols if applicable

• Sample preparation evaluation:

  • Assess cell viability and potential effects of cell death on results

  • Examine effects of different cell isolation methods on epitope accessibility

  • Consider potential downregulation of MHC class I under certain culture conditions

• Experimental design considerations:

  • Review potential confounding variables in the experimental setup

  • Compare results with alternative anti-MHC class I antibodies

  • Implement genetic controls (e.g., MHC class I knockout cells)

• Literature and collaboration:

  • Consult recent publications for updated protocols and potential caveats

  • Contact laboratories with published experience using this antibody

  • "Stay current on recent literature to incorporate new information, for example details about subcellular localization, post-translational modifications, or binding interactions involving your protein"

• Advanced confirmatory approaches:

  • Implement orthogonal methods to confirm observations

  • Consider genetic approaches (CRISPR knockout/knockin) to validate antibody specificity

  • Use mass spectrometry to confirm identity of antibody-targeted proteins

As noted in the literature, "keeping a detailed lab notebook will help when it comes time to write the methods section and publishing, so that peer reviewers and readers will be able to understand exactly how your results were generated" .

How can researchers optimize affinity purification protocols using M1/42.3.9.8 antibody?

Optimizing affinity purification protocols with the M1/42.3.9.8 antibody requires careful consideration of multiple parameters:

• Antibody coupling to solid support:

  • Optimal coupling density: 1-5 mg antibody per mL of Sepharose-4B

  • Coupling chemistry: CNBr-activation for covalent attachment

  • Blocking remaining active sites thoroughly to reduce non-specific binding

• Sample preparation:

  • Cell lysis conditions: Use mild detergents (0.5% DOC recommended) to preserve native protein structure

  • Clearing lysates: High-speed centrifugation (100,000 × g) to remove insoluble material

  • Pre-clearing: Pass lysate through control matrix (no antibody) to reduce non-specific binding

• Column operation parameters:

  • Flow rate: Slow flow rate (0.2-0.5 mL/min) for optimal capture

  • Sample application: Multiple passes or recirculation for maximum binding

  • Washing buffer composition: Gradually increasing stringency to remove non-specifically bound proteins

• Elution conditions:

  • Buffer composition: 0.5% DOC, 0.65 M NaCl, 20 mM Tris, pH 8.0 has been optimized for H-2 elution while maintaining biological activity

  • Collection: Immediate neutralization and collection on ice to preserve activity

  • Fraction analysis: Rapid analysis of fractions to identify protein-containing eluates

• Scale considerations:

  • Documented yields: 110-180 μg H-2d per 10^10 P815 cells

  • Column capacity: Calculate based on expected yield to determine appropriate column size

  • Sample-to-matrix ratio: Optimize to prevent column saturation while maximizing yield

• Quality control of purified MHC molecules:

  • Purity assessment: SDS-PAGE with silver staining or Western blotting

  • Activity testing: Antibody rebinding assays and functional tests (e.g., ability to stimulate alloreactive CTL)

  • Storage conditions: Optimized buffer composition and temperature for maintaining biological activity

This optimized protocol has been demonstrated to yield H-2 antigens that retain both serological and biological activity, making them suitable for downstream applications in immunological research .

How are M1/42.3.9.8 antibody and other anti-MHC antibodies contributing to therapeutic research?

While the M1/42.3.9.8 antibody has primarily been a research tool, similar monoclonal antibodies targeting MHC molecules are increasingly being explored for therapeutic applications. Recent developments include:

The principle of developing therapeutic monoclonal antibodies against specific targets has shown promise in clinical settings. For instance, Vanderbilt University Medical Center recently launched a first-in-human clinical trial to assess an experimental monoclonal antibody against enterovirus D68 (EV-D68) . This illustrates how fundamental research with monoclonal antibodies can translate to therapeutic applications.

For MHC-targeting antibodies specifically, research areas include:

• Transplantation tolerance: Antibodies targeting specific MHC epitopes are being investigated for their potential to induce donor-specific tolerance without global immunosuppression.

• Autoimmunity: MHC-specific antibodies may help modulate aberrant immune responses in autoimmune conditions by interfering with pathogenic T cell activation.

• Cancer immunotherapy: Some research explores blocking or modulating MHC presentation to enhance anti-tumor immune responses or overcome immune evasion mechanisms.

The knowledge gained from basic research with antibodies like M1/42.3.9.8 provides the foundation for these translational approaches, demonstrating how "patient-oriented research led to the discovery of a potent neutralizing antibody, which led back to the clinic" .

What emerging technologies are enhancing the utility of antibodies like M1/42.3.9.8 in research?

Several emerging technologies are expanding the applications and utility of research antibodies like M1/42.3.9.8:

• Advanced conjugation chemistries: Development of site-specific conjugation methods that preserve antibody function while adding reporter molecules, enabling more precise detection and quantification of MHC molecules.

• Multiparameter analysis platforms: Integration with high-dimensional cytometry (mass cytometry, spectral flow cytometry) allows simultaneous analysis of MHC expression alongside dozens of other cellular parameters.

• Single-cell technologies: Combination with single-cell RNA sequencing or proteomics to correlate MHC expression with transcriptional or protein expression profiles at the individual cell level.

• Super-resolution microscopy: Enhanced visualization of MHC distribution and trafficking within cells using antibodies like M1/42.3.9.8 conjugated to appropriate fluorophores.

• Antibody engineering: Modification of antibody frameworks to enhance specificity, affinity, or stability while maintaining epitope recognition:

  • "Antibody Drug Conjugate – general manufacture process" involves sophisticated bioconjugation techniques that could be applied to research antibodies

  • Such approaches include "pH adjust with Tris/EDTA buffer, dilution to concentration, reduction with TCEP, conjugation with payload in solvent"

• In vivo imaging: Development of non-invasive imaging approaches using labeled antibodies to track MHC expression in living organisms.

These technological advances provide researchers with more powerful tools to investigate MHC biology and immune responses, potentially leading to new insights into disease mechanisms and therapeutic approaches.

What are common pitfalls when working with M1/42.3.9.8 antibody and how can they be addressed?

Researchers working with the M1/42.3.9.8 antibody may encounter several common challenges. Here are key pitfalls and their solutions:

When troubleshooting, remember that "you'll want to supplement the vendor's validation data with your own validation testing relevant to your chosen application and model system. Only after re-validating the antibody and optimizing your protocol (when necessary) should you proceed with scale-up and data collection" .

How should researchers evaluate and ensure batch-to-batch consistency of experiments using M1/42.3.9.8 antibody?

Ensuring batch-to-batch consistency is crucial for reproducible research with the M1/42.3.9.8 antibody. Researchers should implement the following quality control measures:

• Reference standard maintenance:

  • Create and maintain an internal reference standard from a well-characterized antibody lot

  • Use this standard to benchmark each new lot before implementing in experiments

• Functional validation protocols:

  • Develop standardized validation assays for each application (flow cytometry, immunoprecipitation, etc.)

  • Test each new batch against established positive and negative controls

• Quantitative assessment parameters:

  • For flow cytometry: Compare mean fluorescence intensity and staining index

  • For immunoprecipitation: Evaluate yield and purity of precipitated proteins

  • For affinity purification: Assess column capacity and recovery of functional protein

• Documentation practices:

  • Maintain detailed records of lot numbers, validation results, and experimental outcomes

  • Document any observed variations between lots and required protocol adjustments

• Storage and handling standardization:

  • Implement consistent storage conditions (-20°C or -80°C, protected from light)

  • Standardize aliquoting procedures to minimize freeze-thaw cycles

  • Document expiration dates and stability testing results

• Vendor communication:

  • Request certificate of analysis for each lot

  • Inquire about production changes that might affect antibody performance

As noted in best practices: "Keeping a detailed lab notebook will help when it comes time to write the methods section and publishing, so that peer reviewers and readers will be able to understand exactly how your results were generated" .

By implementing these comprehensive quality control measures, researchers can minimize variability and ensure reproducible results across multiple experiments and studies using the M1/42.3.9.8 antibody.